Mississauga, September 15, 2015 – The revitalized Canadian biotechnology company, Microbix Biosystems Inc. (MBX:TSX), will make an enthusiastic return to MEDICA, the world’s largest annual medical trade fair, November 16-19 in Düsseldorf, Germany, with a new face and a new product, Toxoplasma gondii Antigen.
The new product comes in two forms: Toxoplasma gondii Antigen, suitable for a wide variety of IgG and other immunoassays and an IgM Grade version designed specifically for IgM assays. Both of these products are best-in-class and have demonstrated they perform better than current market leaders, both in terms of titre and specificity.
“Overall, our sales have continued to climb since last year’s MEDICA but we’re not taking that success for granted,” says Kevin Koole, Microbix Director of Sales and Marketing for the 31-year-old Toronto area company. “So we have come back to the show not only with new energy and our new product, but also with a new look – including a new logo, a new website, and most importantly a new commitment to serving our clients. In particular, we believe our existing client base will very much like what the new toxoplasma antigens can do for them by way of improved sensitivity and specificity of their diagnostic tests.”
Toxoplasma is a common parasitic infection spread primarily by cats and contaminated food. While toxoplasma infection is usually asymptomatic in healthy people, it can cause serious complications to a developing fetus and to the immune compromised (e.g. HIV infected patients). Toxoplasma testing is part of the TORCH diagnostic panel (Toxoplasma, Rubella, CMV, Herpes) routinely administered to expectant mothers in the first trimester of pregnancy.
The new antigens available from Microbix will be used in IgG and IgM antibody detection tests produced by most of the world’s leading diagnostic manufacturers. Many of these companies already use antigens produced by Microbix
Microbix Biosystems Inc. specializes in the research and development of biological solutions, including products for human health applications, namely in the vaccine, therapeutic and diagnostic markets, as well as animal reproductive markets worldwide. The Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company’s pipeline of innovative technologies and products includes LumiSort™ semen sexing technology for the livestock industries and Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.
To learn more about Microbix, we invite you to visit us during MEDICA 2015 at the Ontario/Canada Pavilion, Hall 3, Booth H14
You can also locate us in “Companies & Products" on the medica-tradefair.com portal.
For further information, please contact:
Kevin Koole: email@example.com
+1-905-361- 8910 x228.